AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price traded down 2.4% during trading on Wednesday. The stock traded as low as $284.91 and last traded at $285.9170. Approximately 4,735,965 shares changed hands during trading, a decline of 25% from the average session volume of 6,277,263 shares. The stock had previously closed at $292.82.
AbbVie News Summary
These are some of the ABBV news items that stood out recently:
- Positive Sentiment: Piper Sandler raised its price target to $349 from $303 and maintained an Overweight rating, implying about 23% upside from the prior close. Article: AbbVie Is Near Its High. Piper Sandler Sees Another 23%
- Positive Sentiment: AbbVie plans to invest more than $200 million to modernize its Barceloneta manufacturing campus in Puerto Rico, supporting its production infrastructure. Article: AbbVie to Invest More than $200 Million in Puerto Rico
- Neutral Sentiment: AbbVie will present at the Piper Sandler healthcare conference on December 2; the announcement may provide an opportunity for updates but includes no new business guidance. Article: AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
Wall Street Analysts Forecast Growth
ABBV has been the topic of a number of research analyst reports. Argus lifted their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. UBS Group boosted their price target on shares of AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. Oppenheimer raised their price objective on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Scotiabank upped their price target on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Finally, BNP Paribas Exane raised their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $299.62.
Get Our Latest Stock Report on AbbVie
AbbVie Price Performance
The business’s 50 day simple moving average is $278.98 and its 200 day simple moving average is $242.55. The company has a market capitalization of $505.88 billion, a price-to-earnings ratio of 49.26, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter in the prior year, the business earned $1.86 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, analysts expect that AbbVie Inc. will post 13.98 EPS for the current fiscal year.
AbbVie Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a $1.82 dividend. The ex-dividend date is Friday, January 15th. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. AbbVie’s payout ratio is 125.30%.
Insider Buying and Selling at AbbVie
In related news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This represents a 32.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.
Institutional Trading of AbbVie
A number of institutional investors have recently added to or reduced their stakes in ABBV. Verus Financial Partners Inc. increased its position in shares of AbbVie by 1.7% in the third quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock valued at $536,000 after buying an additional 35 shares in the last quarter. Evergreen Private Wealth LLC increased its position in AbbVie by 3.3% during the 3rd quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock worth $285,000 after purchasing an additional 35 shares in the last quarter. Lifelong Wealth Advisors Inc. raised its stake in AbbVie by 2.1% in the 3rd quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock valued at $459,000 after purchasing an additional 36 shares during the last quarter. IMG Wealth Management Inc. lifted its holdings in AbbVie by 22.8% in the 3rd quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock valued at $51,000 after purchasing an additional 36 shares in the last quarter. Finally, Foundry Financial Group Inc. lifted its holdings in AbbVie by 4.6% in the 3rd quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after purchasing an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Stories
- Five stocks we like better than AbbVie
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
